IP Library › Granted Patent US 9,075,063
Granted Patent B2
US 9,075,063 · App. 13/341,805 · Granted Jul 7, 2015

Methylation analysis to determine the presence of cancer cells

Inventors: Ayako Sakai (Kobe, JP); Atsushi Kaneda (Bunkyo-ku, JP); Kouichi Yagi (Bunkyo-ku, JP); Hiroyuki Aburatani (Bunkyo-ku, JP)
Assignees: THE UNIVERSITY OF TOKYO; SYSMEX CORPORATION
G01N33/57419C12Q1/6886C12Q2600/154G01N2800/52G01N2800/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,075,063
App. No.
13/341,805
Granted
Jul 7, 2015
Kind
B2
Abstract

The present invention relates to a method for determination of the presence or absence of cancer cells in a biological sample or a method for determination of the prognosis of a colorectal cancer patient based on a result obtained by extracting DNA from a biological sample and analyzing methylation status of a marker gene in the DNA.

Claims (11)

1. A method for determination of presence or absence of cancer cells in a tissue obtained from a colon of a subject comprising the steps of:

extracting DNA from the tissue;

carrying out bisulfite treatment to the DNA obtained from the step of extracting;

amplifying DNA of a promoter region of COL4A2 by using the DNA from the bisulfite treatment step as a template, a first primer comprising the sequence of SEQ ID NO: 15 and a second primer comprising the sequence of SEQ ID NO: 16;

obtaining a peak from a methylated DNA fragment and a peak from a non-methylated DNA fragment of the promoter region of COL4A2 by analyzing the amplified DNA by mass spectrometry;

calculating a methylation rate of CpG sites in the promoter region of COL4A2 from an area ratio between a peak from the methylated DNA fragment and a peak from the non-methylated DNA fragment; and

determining presence or absence of cancer cells in the tissue based on a comparison of the rate obtained from the step of calculating to a pre-determined cut-off value, and cancer cells are determined to be present in the tissue when the rate is higher than the cut-off value.

2. The method according to claim 1 , wherein the methylation rate of CpG sites is calculated from the formula:

area of the peak derived from the methylated DNA fragment/(area of the peak derived from the non-methylated DNA fragment+area of the peak derived from the methylated DNA fragment).

3. The method according to claim 1 , further comprising fragmenting the DNA obtained from the step of extracting after the step of extracting.

4. The method according to claim 1 , wherein the first primer has a tag sequence: 5′-AGGAAGAGAG-3′ (SEQ ID NO: 133) at the 5′ terminal of the first primer, and the second primer has a T7 promoter sequence: 5′-CAGTAATACGACTCACTATAGGGAGAAGGCT-3′ (SEQ ID NO: 134) at the 5′ terminal of the second primer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2012
From: ABURATANI, HIROYUKI; YAGI, KOUICHI; KANEDA, ATSUSHI; SAKAI, AYAKO
To: THE UNIVERSITY OF TOKYO; SYSMEX CORPORATION
Reel/Frame 027902/0990 →
Priority Claims (1)
JP 2009-158873 · Jul 3, 2009 · national
Continuity (2)
Continuation PCTJP2010061164 · Jun 30, 2010
Related Publication 20120178634A1 · Jul 12, 2012